Figure 2

sEphB4-HSA inhibited proliferation and induced apoptosis of MPM cell in vivo . (A) sEphB4-HSA (20 mg/kg, 3 times a week) profoundly inhibited H2373 tumor growth in vivo. (B) Representative images of CD31 and Ki67 staining of harvested H2373 tumors showing reduced vessel density and tumor cell proliferation by sEphB4-HSA treatment. CD31 and Ki67 coverage were normalized to DAPI coverage. (C) Representative images of TUNEL staining of harvested H2373 tumors showing induced tumor cell apoptosis by sEphB4-HSA treatment. TUNEL coverage was normalized to DAPI coverage. (D) Representative images of phosphorylated Akt, S6, and Src staining of harvested H2373 tumors showing inhibited PI3K and Src signaling by sEphB4-HSA treatment. At least 4 images from each analysis were used for quantification and statistical analysis. *, P<0.01; **, P<0.002. Error bars indicate standard error of mean.